Stay updated on Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial
Sign up to get notified when there's something new on the Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial page.

Latest updates to the Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial page
- Check4 days agoChange DetectedThe web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.8%
- Check40 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed information about a clinical trial for non-favorable risk AML patients and the addition of a new version revision and collaborators.SummaryDifference14%
- Check54 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.4%
- Check69 days agoChange DetectedDifference0.4%
- Check83 days agoChange DetectedDifference0.4%
Stay in the know with updates to Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial page.